1. Introduction {#s0005}
===============

Breast cancer is the most frequent cancer, 30% of all new cancer diagnoses, in women, and is responsible for roughly half a million total deaths each year worldwide ([@b0195]). According to latest cancer report of [@b0210], the rate of breast cancer is 24.9% in adult Turkish women. Some risk factors influence of developing breast cancer are menstrual history, reproductive factors, hormone use, genetics, family history, diet and exercise ([@b0200]). The loss or inhibition of various ATP-binding cassette (ABC) transporters has been observed to influence tumor cell phenotypes closely associated with malignant potential, including proliferation, differentiation, migration and invasion; these observations have been made across multiple cancer types ([@b0055]).

Multi Drug Resistance (P-glycoprotein, P-gp, ABCB1, MDR1) and Breast Cancer Resistance (BCRP, ABCG2, MXR, ABCP) ABC transporter proteins limit the intracellular concentration of the substrates via energy-dependent (active) pumping out of the cell. ABCB1 and ABCG2 protect the body against endogenous and exogenous xenobiotics with their important roles in intestinal absorption and secretion, hepato- and urinary elimination, and barrier through the placenta, testis and brain ([@b0040], [@b0120], [@b0190]). The single nucleotide polymorphism (SNP) of *ABCB1*, *C3435T* (rs1045642), occurs in exon 26, and the *T* allele appears to be associated with markedly lower P-gp expression compared with the *C* allele ([@b0095]). The SNP has been shown to be correlated with the development of various type of cancer such as colorectal ([@b0085]), acute lymphoblastic leukemia ([@b0240]), glioma ([@b0165]) and renal epithelial tumors ([@b0075]). *ABCB1 C3435T* might reduce protection for cells and potentially contribute to the development of breast cancer ([@b0060], [@b0225]). However, the results have been contradictory ([@b0230]). The *ABCG2 C421A* (rs2231142) in exon 5 is one of the most important genetic variations and results in lower expression levels in the cellular membrane compared with the wild-type protein ([@b0090]). BRCP is also expressed from the apical membrane of alveolar epithelial cells in breast tissue at during pregnancy and lactation and plays a role in the expulsion of accumulated toxins and carcinogens to a woman's milk ([@b0040], [@b0120], [@b0220]). To date, studies have investigated the association between *ABCG2* gene polymorphisms and susceptibility to carcinoma such as non-papillary renal cell carcinoma ([@b0125]), B cell lymphoma ([@b0025]) and prostate cancer ([@b0080]). However, the association between *ABCG2* gene polymorphisms and breast carcinoma risk has been evaluated in only a few studies ([@b0235], [@b0065], [@b0150]).

Prostaglandins play a role in carcinogenesis via the suppression of immune responses, and the inhibition of apoptosis, angiogenesis, tumor cell invasion and metastasis pathways ([@b0020], [@b0130]). Prostaglandin-endoperoxide synthase 2 (COX-2) is an inducible enzyme that plays a major role in the inflammatory response by converting arachidonic acid to prostaglandins. Overexpression of COX-2 has been found in a variety of cancers; thyroid ([@b0215]); colorectal ([@b0050]), gastric ([@b0185]) and breast ([@b0155]). In recent studies, *COX-2 T8473C* (rs5275), *G899C* (rs20417) and *G306C* (rs5277) have been shown to cause an increase in the level of COX-2 expression ([@b0005], [@b0020], [@b0245], [@b0140]). The variants have also been investigated for their role in contributing to breast cancer risk ([@b0145]). However, the results have been inconclusive.

Overexpression of COX-2 can result the over-production of prostaglandins, which are substrates for P-gp and BCRP. The dysfunction or reduced function of P-gp and BCRP proteins can cause carcinogenesis via xenobiotics and the accumulation of inflammatory agents in cells ([@b0015]). Knowledge of ethnic and individual genetic differences is very important for understanding personal reactions in the case of exposure to xenobiotics/drugs ([@b0105], [@b0040]). We accordingly investigated whether the single nucleotide polymorphisms (SNPs) of ABCB1 and ABCG2 carrier proteins and COX-2 enzyme affect breast cancer risk since these genetic differences have not been clarified in Turkish population. We believe that the preliminary study could enrich the scarce literature about the polymorphisms in breast cancer susceptibility.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

We evaluated the influence of *ABCG2*, *ABCB1* and *COX-2* gene polymorphisms on susceptibility to breast cancer in 104 Turkish female patients and 90 ethnic- and age-matched healthy controls between 2012 and 2015. These 104 patients had a mean age of 52 ± 12 years were operated upon at the Acibadem Maslak Hospital Breast Health Centre (Istanbul, Turkey) or admitted for follow-up after breast cancer surgery. Healthy control volunteers with a mean age of 49 ± 14 years who never had any type of cancer were in-patients with various diagnoses (e.g., eye diseases, pulmonary diseases, cardiovascular diseases and neurological disorders) at the Hospital of Istanbul University (Istanbul, Turkey). All participants provided informed consent, and the study was approved by the ethics committees of Istanbul and Acibadem Universities (2011/87-555; 2012/291). Demographic and anthropometric factors were assessed using a short questionnaire. The pathological types of the patients were categorized as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC) or ductal carcinoma in situ (DCIS). We also evaluated the association between patient genotypes and the status of ERα, PgR and HER2.

2.2. Genotyping {#s0020}
---------------

Genomic DNA was extracted from whole blood using standard phenol chloroform extraction protocol and further purification was done by using High Pure PCR Product Purification Kit (Roche, Mannheim, Germany). SNP analysis was performed using a LightCycler FastStart DNA Master HybProbe (Roche, Mannheim, Germany) and custom-designed LightSNiP assay probes (Roche, Mannheim, Germany) according to the manufacturer's instructions. *ABCG2 C421A*, *ABCB1 C3435T*, *COX-2 T8473C* and *COX-2 G306C* were genotyped using a Roche Light Cycler 480 (Roche, Mannheim, Germany) real-time PCR platform and melting curve analyses were performed by the carousel-based system PCR program. In a final volume of 20 mL reaction mix per sample, the following mixtures were added: 1X FastStart DNA Master Mix, 2 mM MgCl~2~, 0.2 mM LightSNP HybProbe, appropriate amount of PCR grade water and 500 ng DNA sample. The plates were sealed and centrifuged at 3000 rpm for a minute. Details of custom-designed LightSNiP assay probes were summarized in [Table 1](#t0005){ref-type="table"} and carousel-based system PCR program setup was given in [Table 2](#t0010){ref-type="table"}.Table 1Reference sequences of custom-designed LightSNiP assay probes.LightSNiPReference SequenceMelting temperatureABCG2 *C421A* (rs2231142)GCACTCTgACggTgAgAgAAAACTTA \[A/C\] AgTTCTCAgCAgCTCTTCggCTTgC57.74 °C for allele \[C\]\
61.92 °C for allele \[A\]ABCB1 *C3435T* (rs1045642)AgCCgggTggTgTCACAggAAgAgAT \[C/T\] gTgAgggCAgCAAAggAggCCAACA55.76 °C for allele \[C\]\
63.05 °C for allele \[T\]COX-2 *G306C* (rs5277)TTCgAAATgCAATTATgAgTTATgT \[C/G\] TTgACATgTAAgTACAAgTgTCTTT53.64 °C for allele \[G\]\
62.30 °C for allele \[C\]COX-2 *T8473C* (rs5275)TTTgAAATTTTAAAgTACTTTTggT \[C/T\] ATTTTTCTgTCATCAAACAAAAACA52.94 °C for allele \[T\]\
61.12 °C for allele \[C\][^1]Table 2Carousel-based system PCR program setup.Program NameCyclesAnalysis ModeTarget (°C)Acquisition ModeHold (sec)Pre-Incubation1None95None600Amplification45Quantification95None1060Single1072None15Melting Curve1Melting Curve95None3040None12075Continuous--Cooling1None40None30

Genotyping was performed by scientists blinded to the patients' case control status. A 10% random sample was genotyped twice for quality assurance. Also, to confirm the genotyping results of the variants, the selected PCR amplified DNA samples (n = 2, for each genotype in the cases and controls) were examined with DNA sequencing. The results were 100% concordant.

2.3. Statistical analysis {#s0025}
-------------------------

The sample size was calculated by an online sample size estimator (<http://osse.bii.a-star.edu.sg>). Hardy-Weinberg equilibrium (HWE) analysis was performed using the Chi-square (χ^2^) test. For the analysis of genotype frequencies, the wild-type category (chosen either as the most common wild-type frequency or arbitrarily if the two alleles exhibited similar frequencies) was used as the reference group. Data comparisons were done by using Fisher's exact test. To evaluate the association between the genotype frequencies and breast cancer, odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. All of the statistical analyses were performed using Statistical Package for Social Sciences (SPSS) software (Version 17; SPSS Inc, Chicago, IL, USA). A two-sided *p* value less than 0.05 was considered to be statistically significant.

3. Results and discussion {#s0030}
=========================

Although the correlation between the SNPs of the *ABCG2*, *ABCB1* and *COX-2* genes with breast cancer risk has been reported in some studies, no meaningful relationship has been demonstrated thus far. The substrate specificities of ABCG2 and ABCB1 are quite similar, and ABCG2 and ABCB1 are involved in the transport of COX-2 mediated inflammatory agents ([@b0120], [@b0245]). Therefore, we evaluated the association between functional and common variants (*ABCG2 C421A*, *ABCB1 C3435T*, *COX-2 T8473C* and *COX-2 G306C*), and susceptibility to breast cancer in a cohort of Turkish women.

Firstly, we determined that no significant differences in age (52.4 ± 12.5 vs. 49.4 ± 14.2 years) or BMI (27.9 ± 5.3 vs. 24.5 ± 4.5 kg/cm^2^) between the breast cancer and control groups, respectively, suggesting that the matching based on these two variables was adequate. Secondly, the genotype distributions did not significantly deviate from the HWE in either the case or control groups for any of the examined SNPs (*p* \> 0.05). After determining a lack of bias among the study populations, the differences between cases and controls in the distributions of *ABCG2 C421A*, *ABCB1 C3435T*, *COX-2 T8473C* and *COX-2 G306C* genotypes were analyzed ([Table 3](#t0015){ref-type="table"}).Table 3Genotype distributions and features of the studied SNPs.FrequenciesSNPsAmino acid changeVariant alleleGenotypesCases (n = 104, %)Controls (n = 90, %)OR (95% CI)*p valueABCG2 C421A* (rs2231142)*CC*90 (86.5)61 (67.7)*CC* vs. any *A*\
3.06 (1.49--6.25)0.002\*Q141K*CCA*14 (13.5)25 (27.7)*AA*0 (0.0)4 (4.4)**MAF0.0720.183**  *ABCB1 C3435T* (rs1045642)*CC*25 (24.2)16 (18.1)*CC* vs. any *T*\
1.24 (0.61--2.53)0.361I1145I*CCT*37 (35.9)40 (45.4)*TT*41 (39.8)32 (36.3)**MAF0.4220.418**  *COX-2 G306C* (rs5277)*GG*46 (44.6)39 (43.3)*GG* vs. any *C*\
1.06 (0.59--1.86)0.853V102V*G,GC*47 (45.6)36 (40.0)*CC*10 (9.7)15 (16.7)**MAF0.3250.366**  *COX-2 T8473C* (rs5275)*TT*72 (69.2)58 (64.4)*TT* vs. any *C*\
1.24 (0.68--2.26)0.479--*TTC*28 (26.9)28 (31.1)*CC*4 (3.8)4 (4.4)**MAF0.1730.200**[^2]

The *ABCG2 C421A* variant has been shown to be associated with a reduction of BCRP protein expression, and therefore decreased carrying capacity ([@b0090]). The protein expression in subjects with the *C421A* mutant variant is reduced compared with that of patients carrying the wild-type variant ([@b0170]). While the incidence of the *ABCG2 C421A* polymorphism is 30% in Far Easterners, it has been reported to be approximately 10% and 13% in Caucasians and Middle Easterners, respectively ([@b9000]). [@b0065] found that the most frequent genotype in patient groups was the *AA* genotype; its frequency was significantly different from that of the control subjects (*p* = 0.04). In the present study, *CC* genotype was the most frequent genotype in both our case and control groups, unlike to Kurdish populations in Sanadaj-Iran in comparison with [@b0065]. [@b0235] investigated the correlation between the *ABCG2 C421A* polymorphism and breast cancer susceptibility in 1169 patients with breast cancer and 1244 healthy controls. The authors showed that the *ABCG2 C421A AA* genotype was significantly associated with an increased risk for developing breast carcinoma (*p* = 0.033). According to our results, *ABCG2 C421A* was significantly associated with an increased risk of breast cancer (*p* = 0.0019). However, the patients carrying the *CC* genotype interestingly had a higher risk of disease compared with the patients carrying any *A* allele (OR = 3.06; 95% CI = 1.49--6.25) ([Table 3](#t0015){ref-type="table"}). We indicate the results should be confirmed with the larger group because the frequency of the patients carrying *AA* genotype was ≤ 4.4%. The other variants, *CA* and *AA* genotypes, might be not associated with breast cancer (*p ≥* 0.632) ([Table 3](#t0015){ref-type="table"}).

Many epidemiological studies have examined the relationship between *ABCB1* polymorphisms and breast cancer. [@b0225], in a meta-analysis, evaluated 10 case-control studies that encompassed 5282 breast cancer patients and 7703 healthy controls. It was suggested that *ABCB1 C3435T* polymorphism might contribute to individual susceptibility to breast cancer. The recent studies have demonstrated a significant difference in the distribution of *C* and *T* alleles between breast cancer patients and healthy controls ([@b0010], [@b0070], [@b0160]). However, some studies failed to find a significant relationship ([@b0150], [@b0065]). [@b0205] assessed the relationship between breast cancer risk and the *ABCB1 C3435T* variant in 50 healthy volunteers and 57 breast cancer patients in Turkish population. They found the polymorphism was associated with a 1.5-fold increase in breast cancer risk. However, we found no relationship between the *ABCB1 C3435T* variant and breast cancer development (OR = 1.242, 95% CI: 0.61--2.53; *p* = 0.36) ([Table 3](#t0015){ref-type="table"}).

*COX-2 T8473C* is a common polymorphism associated with several cancers in different ethnic populations ([@b0110]). Thus far, more than 20 *COX-2* genetic variations have been investigated for the risk of breast cancer ([@b0035]). However, [@b0145] have been assessed the results as conflicting. In a recent meta-analysis, [@b0110] found that the *COX-2 T8473C* gene polymorphism might not be a risk factor for breast cancer among Caucasians. Three studies focused on *COX-2 G306C* and the risk of breast cancer, however, failed to find any significant relationship between polymorphism and breast cancer risk ([@b0045], [@b0005]). Similarly, we did not find any significant differences in *COX-2* gene variants between breast cancer patients and the control group ([Table 3](#t0015){ref-type="table"}).

As it is well known, ERα plays an important role in the progression of breast cancer. Patients with high ERα or PgR expression have a better prognosis. It has been shown that E2-mediated downregulation of P-gp expression occurs in ERα-positive human breast cancer cells and possibly also in normal breast tissues ([@b0100]). In addition, estrogenic activity has been shown to downregulate P-gp expression via post-transcriptional processes in ERα-positive cell lines, leading to increased cellular uptake of P-gp substrates ([@b0175]).

Some studies have been reported that no statistically significant association between *ABCB1 C3435T* and *ABCG2 C421A* polymorphisms and tissue expression of ERα, PgR, HER2/neu, and Ki67 ([@b0065], [@b0150]). Comparing the pathological parameters with the variants, we found that the *ABCB1 C3435T C* allele was less frequent in breast cancer patients with ERα-positive (OR = 2.25; 95% CI: 0.75--6.76; *p* = 0.041) and PgR (OR = 3.67; 95% CI: 1.34--10.03; *p* = 0.008) status. No significant differences in HER2 status, triple negative status (none of ERα-, PgR and HER2 expressed) or pathological type were found with the variants ([Table 4](#t0020){ref-type="table"}).Table 4Relations between polymorphisms and clinicopathological characteristics.VariablesNo. of patients (%)*ABCG2 C421A* (rs2231142)*p* value*ABCB1 C3435T* (rs1045642)*p* value*COX-2 G306C* (rs5277)*p* value*COX-2 T8473C* (rs5275)*p* value*CCCAAACCCTTTGGGCCCTTTCCC*Pathological type0.6570.9750.0560.080 IDC61 (58.7)53801622234514225324 ILC8 (7.7)710233710323 DCIS8 (7.7)620133602251 unknown27 (25.9)ERα status0.3670.041\*0.0620.896 positive57 (54.8)49801226194031423295 negative17 (16.3)16106291520692 unknown30 (28.9)PgR status0.9040.008\*0.4490.896 positive42 (40.4)4260112413359329234 negative31 (29.8)2330741519509152 unknown31 (29.8)HER2 status0.1080.8780.9270.399 positive16 (15.4)124045712314102 negative56 (53.8)51501421214013324257 unknown32 (30.8)Triple negative0.9870.3170.5960.675 yes8 (7.7)710314710251 no63 (60.5)55801525234515326316 unknown33 (31.7)[^3]

Based on the results reported by [@b0065], the *A* allele of the *ABCG2 C421A* variant was associated with IDC (*p* \< 0.05). [@b0235] found that an association between this polymorphism and ER and PgR status in breast cancer patients. However, we not find any relationship between the clinicopathological status of breast cancer patients and the *ABCG2 C421A* polymorphism ([Table 4](#t0020){ref-type="table"}). Similarly, [@b0150] did not find a significant difference in the distribution of the *ABCG2 C421A* variant between breast cancer patients and healthy controls; there was also no difference based on the clinical status of the patients (*p* \> 0.05).

Like other studies ([@b0135], [@b0180]), we did not find a significant correlation between *COX-2* SNPs and the clinical status of breast cancer patients ([Table 4](#t0020){ref-type="table"}).

4. Conclusion {#s0035}
=============

We observed that *ABCG2 C421A* was significantly associated with an increased risk of breast cancer (*p* = 0.0019). No studies have demonstrated the prevalence of the *ABCG2 C421A* polymorphism in Turkish society and its relationship to breast cancer; our results are the first data. *ABCB1 C3435T* did not exhibit any relationship with breast cancer development. However, we found significant differences between *ABCB1 C3435T* variant and ERα and PgR status with breast cancer in our population of Turkish women. *ABCB1 C3435T* might be associated with a potential risk for breast cancer in Turkish women. These data might be useful for identifying individuals at risk of developing breast cancer. However, our results were obtained with a limited sample size; we were accordingly only able to draw preliminary conclusions at this time. Future studies based on larger, stratified case-control populations are still necessary to clarify the different effects of the *ABCB1, ABCG2* and *COX-2* polymorphisms on cancer risk. Larger sample sizes and functional assays will be required to confirm our findings.
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[^1]: rs: reference SNP number; alleles in the square brackets indicates the polymorphisms.

[^2]: SNPs, single nucleotide polymorphisms; rs, reference SNP number; MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence intervals. \**p \< 0.05* indicates statistical significance.

[^3]: IDC, Invasive ductal carcinoma; ILC, Invasive Lobular Carcinoma; DCIS, Ductal carcinoma in situ; ERα, estrogen receptor-α; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. \**p \< 0.05* indicates statistical significance.
